MX377190B - Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide. - Google Patents

Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.

Info

Publication number
MX377190B
MX377190B MX2016006595A MX2016006595A MX377190B MX 377190 B MX377190 B MX 377190B MX 2016006595 A MX2016006595 A MX 2016006595A MX 2016006595 A MX2016006595 A MX 2016006595A MX 377190 B MX377190 B MX 377190B
Authority
MX
Mexico
Prior art keywords
rheumatoid arthritis
treatment
il6r antibody
antibody
il6r
Prior art date
Application number
MX2016006595A
Other languages
English (en)
Spanish (es)
Other versions
MX2016006595A (es
Inventor
Allen Radin
Chungpeng Fan
Hoogstraten Hubert Van
Adelsberg Janet Van
Mark Genovese
Martine Jasson
Stefano Fiore
Vanessa Marks
Xiaohong Huang
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of MX2016006595A publication Critical patent/MX2016006595A/es
Publication of MX377190B publication Critical patent/MX377190B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016006595A 2013-11-22 2014-11-21 Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide. MX377190B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361907796P 2013-11-22 2013-11-22
US201462008787P 2014-06-06 2014-06-06
EP14306366 2014-09-05
PCT/US2014/066856 WO2015077582A1 (en) 2013-11-22 2014-11-21 Compositions for the treatment of rheumatoid arthritis and methods of using same

Publications (2)

Publication Number Publication Date
MX2016006595A MX2016006595A (es) 2016-09-06
MX377190B true MX377190B (es) 2025-03-07

Family

ID=51518724

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006595A MX377190B (es) 2013-11-22 2014-11-21 Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
MX2020011993A MX2020011993A (es) 2013-11-22 2016-05-20 Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020011993A MX2020011993A (es) 2013-11-22 2016-05-20 Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.

Country Status (11)

Country Link
US (1) US20160280782A1 (enExample)
EP (2) EP3071230B1 (enExample)
JP (4) JP6657089B2 (enExample)
KR (4) KR20230155586A (enExample)
CN (2) CN106413748A (enExample)
AU (3) AU2014352801B2 (enExample)
CA (1) CA2930615C (enExample)
MX (2) MX377190B (enExample)
PL (1) PL3071230T3 (enExample)
SG (1) SG10201804000TA (enExample)
WO (1) WO2015077582A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
KR20230155586A (ko) * 2013-11-22 2023-11-10 사노피 바이오테크놀로지 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
BR112018008900A8 (pt) 2015-11-03 2019-02-26 Regeneron Pharma composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
KR20230093522A (ko) * 2016-03-07 2023-06-27 사노피 바이오테크놀로지 류마티스 관절염의 치료를 위한 조성물 및 방법
EP3216461A1 (en) * 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
KR102871642B1 (ko) 2017-12-07 2025-10-15 자크로스 가부시키가이샤 포트가 부착된 백 및 캡이 부착된 백
KR20260109977A (ko) 2018-08-29 2026-07-13 리제너론 파아마슈티컬스, 인크. 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물
JP7542543B2 (ja) * 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
JP2022545312A (ja) * 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
CA3142710A1 (en) * 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
JP7373958B2 (ja) 2019-09-27 2023-11-06 株式会社日立製作所 分析システム及び分析方法
KR20210040735A (ko) 2019-10-05 2021-04-14 양수현 천장 수납형 빨래 건조대
US12254347B2 (en) * 2021-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Data pipeline

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
PT3071230T (pt) * 2013-11-22 2020-06-26 Regeneron Pharma Composições para o tratamento da artrite reumatoide e métodos de utilização das mesmas
KR20230155586A (ko) * 2013-11-22 2023-11-10 사노피 바이오테크놀로지 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법

Also Published As

Publication number Publication date
KR20260060447A (ko) 2026-05-04
PL3071230T3 (pl) 2020-09-21
EP3770173A1 (en) 2021-01-27
MX2020011993A (es) 2021-01-29
CA2930615C (en) 2023-04-04
AU2024204881A1 (en) 2024-08-15
JP2022033891A (ja) 2022-03-02
KR20230155586A (ko) 2023-11-10
WO2015077582A1 (en) 2015-05-28
KR20160079121A (ko) 2016-07-05
AU2014352801A1 (en) 2016-06-23
JP2024026223A (ja) 2024-02-28
JP6657089B2 (ja) 2020-03-04
EP3071230B1 (en) 2020-04-08
MX2016006595A (es) 2016-09-06
CN106413748A (zh) 2017-02-15
JP2016539125A (ja) 2016-12-15
JP2026032035A (ja) 2026-02-25
AU2020223706B2 (en) 2024-04-18
SG10201804000TA (en) 2018-07-30
KR20220056254A (ko) 2022-05-04
US20160280782A1 (en) 2016-09-29
EP3071230A1 (en) 2016-09-28
CA2930615A1 (en) 2015-05-28
CN120514847A (zh) 2025-08-22
AU2020223706A1 (en) 2020-09-10
AU2014352801B2 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
MX2021015309A (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso.
MX2020011993A (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
ECSP17063327A (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX380520B (es) Anticuerpos receptores de antitransferina y métodos de uso.
MX2017001599A (es) Anticuerpos novedosos y sus usos.
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
MX375020B (es) Anticuerpos anti-alfa-sinucleina y métodos de uso.
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
UA123202C2 (uk) Антитіло до тау-білка і його застосування
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
JO3607B1 (ar) مضادات الأجسام المضادة لإنترفيرون ألفا وأوميجا
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
EA201592203A1 (ru) Способы лечения таупатии
MX385854B (es) Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
CL2018000298A1 (es) Anticuerpos anti-cd154 y métodos de uso de estos.
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
MX378749B (es) Agentes para neutralizacion de influenza.
BR112018067851A2 (pt) composições e métodos para o tratamento de artrite reumatoide
EA201891594A1 (ru) Антитела к il-17c
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)

Legal Events

Date Code Title Description
FG Grant or registration